The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Subscribe To Our Newsletter & Stay Updated
